• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BioAdvance drops $3.2m on device, drug bets

January 17, 2018 By Sarah Faulkner

Prescription drugsEarly-stage life science fund BioAdvance announced that it has added an array of new companies to its portfolio, investing nearly $3.2 million into companies from the mid-Atlantic region of the U.S.

Two of the firm’s largest investments went to Opsidio, a Bryn Mawr, Penn.-based company developing monoclonal antibodies to treat fibrotic diseases, and New York-based Pillo Health, which is working on an interactive home healthcare hub. Both companies landed $500,000 contributions from BioAdvance.

“Our goal is to invest more money into the region’s rich innovation pipeline this fiscal year than in prior years, while maintaining our investment standards, and we achieved that goal in the first six months,” CEO Barbara Schilberg said in prepared remarks.

“We continue to see an interesting diversity of early-stage opportunities leading to new investments – with more in the pipeline – plus we continue to support our current companies as they progress. We are pleased to continue our role as an active life sciences investor in the region.”

BioAdvance also contributed $400,000 apiece to Oncoro Medical, which is developing a product that integrates patient EMR, genetic information and imaging data to create personalized radiation treatment plans, and to PeriRx, a Broomall, Penn.-based company creating a saliva-based molecular test to detect lung cancer.

Other investments included a $500,000 contribution to TalexMedical, which is commercializing a non-surgical ear molding device to correct misshapen ears in newborns, a $250,000 investment in a company developing anti-infective agents to fight drug-resistant Gram-negative pathogens, VenatoRx, and a $370,000 bid to Relmada Therapeutics, which is testing a compound for major depressive disorder.

Finally, the life science fund invested $50,000 into Curative Orthopedics, which is developing non-invasive orthopedic products to relieve night-time back pain, $30,000 into Enzium, which is developing assays for the detection of direct-acting oral anticoagulant levels based on proteases, $150,000 into WellSheet, which is developing a product that brings together EHR content into a one-page sheet for the doctor, and $40,000 into Group K Diagnostics, which is developing a point-of-care microfluidic diagnostic device.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diagnostics, Drug-Device Combinations, Featured, Funding Roundup, Oncology Tagged With: bioadvance

IN CASE YOU MISSED IT

  • Dexcom updates CGM receiver recall that led to serious adverse events
  • Abbott reports momentum with Libre CGM business as new dual sensor will ‘accelerate’ growth
  • Johnson & Johnson wins FDA priority review for drug delivery system
  • Glucose monitoring company LifeScan files chapter 11 to reduce debt
  • Medtronic enrolls first patient in study for Onyx liquid embolic system

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS